Abstract. Glioblastoma (GBM) is the most common and fatal malignant tumor type of the central nervous system. GBM affects public health and it is important to identify biomarkers to improve diagnosis, reduce drug resistance and improve drug resistance (e.g., personalized targeted therapies). Hedgehog (HH) signaling has an important role in embryonic development, tissue regeneration and stem cell renewal. A large amount of evidence indicates that both normative and non-normative HH signals have an important role in GBM. The present study reviewed the role of the HH signaling pathway in the occurrence and progression of GBM. Furthermore, the effectiveness of drugs that target different components of the HH pathway was also examined. The HH pathway has an important role in reversing drug resistance after GBM conventional treatment. The present review highlighted the relevance of HH signaling in GBM and outlined that this pathway has a key role in the occurrence, development and treatment of GBM.

1. Introduction

Primary central nervous system (PCNS) tumors account for 12% of all neoplasms (1). Glioblastoma (GBM) is the most common type of primary malignant CNS tumor, representing ~48% of all primary malignant CNS tumors and 57% of all gliomas (2). In spite of the progress made in the treatment of GBM in recent years (including surgery, radiotherapy, chemotherapy and targeted therapy), the overall prognosis is still not ideal and the long-term survival rate is low. Certain studies indicated that teenagers and young adults account for 27% of all PCNS tumor cases and the average age was 29 years (1,3). If patients are diagnosed with cancer in those busy years of their life, this may take a serious toll on both their body and mind, and in turn on their spouses and offspring (4). Upon diagnosis, the prognosis of GBM is poor, with months to a year left to live, so that this may also have detrimental effects on the patients’ dependents and family (4).

In recent years, important advances have been made in the exploration of the molecular pathogenesis of tumorigenesis and progression, but this has not been applied to significantly improve patient prognosis. It is thus essential to identify biomarkers for diagnosis, as well as means of reducing drug resistance and delivering treatments, including personalized targeted therapies in the study of GBM. The role of Hedgehog (HH) signaling in the pathophysiology of GBM is underscored by a growing number of publications (5-7). The HH pathway is increasingly being revealed to have an important role in the growth, progression, prognosis and treatment of GBM (8-10).
The present review will discuss the contribution of HH signaling in the development and treatment of GBM. Chemotherapy, targeted therapy and radiotherapy in the HH pathway will also be discussed and the issue of improving partial drug resistance through this pathway will be addressed.

2. Overview of GBM

GBM originates from the glial stem or progenitor cells and is characterized by molecular heterogeneity, with a mean survival of only 15 months after diagnosis (11). Commonly mutated genes and core pathways in sporadic GBM were identified based on molecular mapping and three major GBM subpopulations were identified in combination with other dimensions (gene expression, DNA methylation). The DNA methylated α group amplified cyclin-dependent kinase (CDK)4 and platelet-derived growth factor in the three ways (classical gene expression; classical like; receptor tyrosine kinase II). High-frequency amplification of EGFR and homozygous deletion of CDK inhibitor 2A/B occurred in the DNA methylation group. Mesenchymal/mesenchymal subtypes are abundant in tumors with loss of neurofibromatosis type 1 and increased tumor macrophage infiltration (12,13). The above three types are the most common types of GBM and all involve mutations in telomerase reverse transcriptase promoters (14,15). In addition, characteristic epigenetic patterns are associated with certain putative driving mutations that are important in GBM, according to recent studies (16,17). Examples include mutated isocitrate dehydrogenase (IDH)1 and IDH2, H3.3 histone A or H3 clustered histone 2 mutations, particularly H3K27M in diffuse midline glioma and H3G34R/H3G34V mutations in young patients with GBM (16,17). However, their clinical implication for these GBM subtypes has not been proven. These studies indicate that different subtypes of GBM are caused by different oncogenes, which paves the way for the exploration of highly specific personalized targets.

GBM is characterized by continuous vascularization, tissue invasion and metastasis, metabolic recombination or alternation, immune regulation and promotion of the tumor microenvironment. All of the above characteristics lead to high resistance of GBM to radiotherapy and chemotherapy, which brings a non-negligible challenge to the treatment of the disease (18).

GBM has different subtypes, but the current international treatment methods mainly include chemotherapy [such as temozolomide (TMZ)], radiotherapy (RT) and surgical treatment. Monotherapy will be well tolerated in elderly patients (>65 years) with poor functional status. It has been reported that low-grade RT (40 Gy/15 doses of 2.67 Gy over 3 weeks) was higher than the standard 60 Gy for 6 weeks (19,20). Relapsing patients may be treated with surgery (as palliative care only) or other options include TMZ reactivation, nutrition and bevacizumab. However, there is no specific clinical evidence of prolonged survival (21,22). Several valuable clinical trials are under development for the treatment of GBM, including targeted molecular (precise) therapies (targeting gene mutations and associated signaling pathways, DNA damage repair, tumor metabolism), checkpoint inhibitors/immunomodulation agents and viral therapies. Despite the GBM treatment options available, metastatic disease remains a great concern. Therefore, it is of marked importance to find novel therapeutic targets and new drugs targeting the HH signaling pathway to regulate the occurrence, development, treatment and chemotherapy resistance of GBM (23,24).

3. The HH signaling pathway

HH is a morphogenetic gene, which is highly conserved from drosophila to humans. The HH signaling pathway has an important role in embryonic development, cell proliferation, differentiation and maintenance of tissue polarity (25). Inactivation of this pathway during development may lead to congenital defects, while over-activation in adults is related to tumorigenesis (26,27). The HH protein family includes Sonic HH (SHH), Indian HH (IHH) and desert HH (DHH) (28). In mammals, the mechanism of HH signaling is complex and occurs in primary cilia (PC) (29). In PC, HH protein binds to 12 transmembranes (TM) receptors [Patch1 (PTCH1) and PTCH2] to activate pathways, so that 7-TM protein smoothened (SMO) is inhibited (30). The HH signal is transmitted downstream of SMO through the complex composed of kinesin 7 (KIF7), suppressor of fused homolog (SUFU) and full-length glioma-associated oncogenes (GliFL), which promotes the dissociation of SUFU from GLI protein and then releases transcription factors (GLI1, GLI2 and GLI3) (31,32). GLI2 and GLI3 constitute GliFL, which act as both GLI activators (GLIA) and GLI inhibitors (GLIR) (33,34). After activation of SMO, GLI2/3 P1-6 clusters were dephosphorylated and separated from SUFU (35), which facilitates the transfer of GLIA into the nucleus and the initiation of the transcription of target genes, and their pathway genes (PTCH1, GLI1) (36,37). GLI1 is the main HH target gene and its expression further promotes the activation of the HH signaling pathway at the transcriptional level (38). KIF7, in turn, coordinates HH signaling at the top of the PC and avoids GLI3 from cracking into an inhibited form in response to HH (39). This GLI transcription factor signal transduction pathway is the canonical HH signaling pathway (Fig. 1A).

When HH ligand is absent, PTCH inhibits the activity of SMO by inhibiting the translocation of SMO in PC (40). GliFL is phosphorylated by protein kinase A (PKA), glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1), and then recognized by β-trCP and cleaved into GLIR (41,42). This results in the proteolytic cleavage of GliFL into the form of a C-terminal truncated repressor known as a GLIR (33). SUFU is a negative regulator that binds to GLI proteins and prevents them from migrating to the nucleus (43). GLIR enters the nucleus, binds to HH target gene promoters and inhibits their expression (Fig. 1B).

HH signaling, canonical and non-canonical signaling, exist in parallel, and the mechanisms are complex. Non-canonical HH signaling is the most common HH-dependent reaction process, independent of GLI transcription factors or PC (44). Non-canonical HH signaling pathways may be divided into type I (independent of SMO) and type II (dependent on SMO) (45).

The canonical HH pathway is related to tumorigenesis and detransformation development. In adults, this signal abnormality has a key role in promoting the proliferation and differentiation of numerous tumor types. Its carcinogenic
mechanisms mainly include abnormal cell differentiation, neovascularization, epithelial-mesenchymal transition (EMT) and enhanced invasiveness (46-48). Initially, HH signaling was mainly studied in brain cancer, skeletal muscle and skin cancer (49-51). However, in recent years, studies have indicated that this pathway is abnormal in numerous tumor types, including stomach, pancreas, lung and breast tumors (52-54). As HH signaling is activated in various types of cancer and contributes to cancer proliferation, progression and invasiveness, the HH signaling pathway is anticipated to provide new targets for cancer therapy.

4. Molecular mechanisms of the HH signaling pathway in GBM

HH signaling pathway and GBM microenvironment. The tumor microenvironment/stroma is closely related to tumorigenesis, metastasis and invasion (55,56). The tumor
microenvironment/stroma is mainly composed of endothelial cells, adipocytes, immune cells and cancer-associated fibroblasts (CAFs) (57). CAFs are able to secrete soluble factors to stimulate cancer cells, thereby triggering tumor metastasis and chemotherapy resistance (58-60). Recombinant human Sonic HH N-terminal peptide (rhSHH) enhances HH signaling, accompanied by increased mRNA and protein levels of matrix metalloproteinase-2 (MMP2) and MMP9. Furthermore, the
protein expression of GLI1 was positively associated with the protein expression of MMP-2 and -9, which promoted the adhesion and invasion of GBM cells (60). It has been reported that gap junctions have a role in tumor growth and progression. Torrisi et al (61) modulated SHH signaling and connexin 43 (CX43)-based intercellular communication in an in vitro model. Modulation of SMO with the use of a known agonist (i.e., taxamine) and a known antagonist (i.e., cyclodopamine) affected CX43 expression levels and thus affected related functions. In addition, SMO activation also promoted cell proliferation and migration. Of note, inhibition of the CX43 channel prevented the SMO-induced effects (61).

Therefore, further exploration of the mechanisms of the HH signaling pathway in the tumor microenvironment may lead to better targeting of this pathway to fight cancer.

**Regulatory mechanism and role of SHH in GBM cells.** In the development of GBM disease, PC serve as cell antennae to transmit and regulate a variety of signaling pathways and SHH is one of the most important pathways. SHH levels are significantly increased in GBM cells compared with normal brain tissue and SHH overexpression induced neuroectodermal angiogenesis during mouse embryonic development (62-64). A study has indicated that Fms-related tyrosine kinase 1 (FLT1) is significantly increased in GBM cells and overexpression of FLT1 increased the expression of SHH in cells (64). Knockdown of SHH reduced the migration and invasion mediated by FLT1 overexpression, while overexpression of SHH restored the migration and invasive ability of FLT1 knockdown (64). FLT1 is a tyrosine kinase receptor that binds VEGF-A with several times the affinity of other kinases inserted into domain receptors and has been reported to promote tumor growth and metastasis (65). VEGF-A is one of the key factors promoting tumor angiogenesis and activation of the VEGF-A pathway requires the binding of VEGF-A to its receptor FLT1 to generate downstream signals to stimulate the proliferation and development of tumor cells and provide tumor blood vessels for the growth and metastasis of GBM (64,66). In addition, brain tumorigenic-initiating cells produce DHH ligands to realize the paracrine DHH/PTCH2 signaling cascade, transmit high permeability and angiogenesis, and also promote GBM growth (6). Chen et al (67) reported that C-terminal binding protein 2 (CtBP2) expression was increased and zinc finger and BTB domain containing 18 (ZBTB18) expression was decreased in GBM tissues, and the two were negatively correlated. CtBP2 short hairpin (sh)RNA interacts with ZBTB18 to block cells in G0/G1 phase, inhibit the SHH-Gli1 pathway and reduce the tumor volume (67). However, whether this effect is exerted by increasing SHH gene expression has remained to be elucidated. Therefore, targeted FLT1 or CtBP2 therapy may be a promising direction to develop anti-metastasis agents.

GBM develops through a complex interlocking signaling pathway. RhSHH enhances the HH signaling pathway, which increases the production of MMP-2 and -9 through the PI3K/AKT pathway, thereby regulating migration and invasion of basal membrane cells and promoting GBM cell adhesion, invasion and migration (60). By contrast, triggering the vasoactive intestinal peptide receptor system is triggered to reduce GBM cell migration and invasion through PKA-dependent PI3K/AKT and SHH/GLI1 pathway blocking (68). Similarly, Henao-Restrepo et al (69) reported that PI3K/AKT/mammalian target of rapamycin complex 1 (mTORC1) and SHH/GLI1 signaling pathway proteins were expressed differently in human gliomas with different tumor types and grades, suggesting that the activation of these signaling networks is related to the occurrence and development of high-grade gliomas.

Multiple studies have indicated that the SHH signaling pathway promotes the plasticity of cancer cells by regulating the adhesion between cells and the extracellular matrix, thus increasing the motility and aggressiveness of cells, leading to poor prognosis of patients (60,65,67,68). Statistical analysis of the The Cancer Genome Atlas (TCGA) dataset (TCGA-Glioblastoma June 2016) suggested that SHH upregulation was associated with decreased overall survival (64).

Hedgehog-interacting protein (HHIP), which is located on chromosome 4q31.21-31.3, is defined as an antagonist of SHH, IHH and DHH. Chang et al (9) were the first to demonstrate that the expression of HHIP determined by immunohistochemistry is an independent prognostic marker of favorable outcomes in patients with GBM.

**Expression and role of GLI1 in GBM.** Although GLI1 was originally identified as the amplified gene in malignant human gliomas (70), GLI1 amplification is infrequent in most cancers such as GBM (71). However, since GLI1 is a vital downstream target of the HH pathway, the mRNA level of GLI1 is a reliable indicator of HH pathway activity, this suggests that control of GLI1 protein conversion is critical for GLI-dependent transcription and regulation of the HH signaling pathway (53). And GLI1 protein levels are upregulated in a variety of cancers, and high levels of GLI1 are often associated with tumor progression (72,73). Low GLI1 mRNA levels were similarly negatively correlated with survival in patients with GBM. GLI1 mRNA expression in GBM was significantly lower than in patients with high-HH-medulloblastoma (MB) but significantly higher than in patients with low-HH-MB, and GLI1 mRNA expression is a single continuous distribution, rather than being discrete high/low clusters (5,74). GLI1 promotes the nuclear import of GLI1 into GBM multiforme cells through its transcription factor Forkhead box M1 (FOXM1), thereby increasing the expression of its target genes (75).

Zhou et al (73) reported that in GBM cells, ubiquitin specific peptidase 48 (USP48) gene knockout inhibited cell proliferation and downstream GLI1 target gene expression, thereby inhibiting glioblastoma by USP48 removing ubiquitin-binding compounds on GLI1 and thereby inhibiting GLI1-dependent proteasome degradation. In addition, to a certain extent, GLI1 determines the effect of USP48 on cell proliferation and tumorigenesis and the HH pathway also induces USP48 expression via GLI1 trans-activation, thus forming a mutual feedback loop (73). Similarly, Chang et al (8) indicated that Engrailed 1 (EN1) was highly expressed in GBM cells and tissues and positively regulated GLI1 levels. In addition, EN1 also affected HH signal transduction by regulating PC length and the PC transport-related protein TUB-like protein 3, a PC transport-related protein, to control the proliferation, colony formation, migration and tumorigenesis of GBM cells in vivo. Truncated GLI1 (TGGL1) acted as a functionally enhanced GLI1 with an enhanced ability to promote angiogenic heparanse expression. In vivo and in vitro, TGGL1 is more...
likely to promote GBM angiogenesis and growth than GLI1. Therefore, TGLI1 is a novel mediator promoting GBM angiogenesis through the HH signaling pathway and heparinase is a novel transcriptional target of TGLI1, providing new clues for molecular pathways of tumor angiogenesis and invasive growth (76).

It was observed that both the activation of metabolic glutamate receptor subtype 4 and naringin are able to inhibit the expression of GLI-1 in cells and affect HH signaling pathway transduction, thus inhibiting cell proliferation and promoting cell apoptosis to inhibit the growth of GBM cells (77,78). These may be potential drug targets for controlling GBM cell growth by blocking HH signaling.

Expression and role of GLI2 in GBM. Molecular crosstalk is present between mTORC1/2 and HH pathway activity (71,79,80). In GBM, higher mTORC2 activity enhances the expression of several HH pathway molecules (GLI1, GLI2 and PTC1). A further study by Maiti et al (80) indicated that mTORC2 inhibits GLI2 ubiquitination by inactivating GSK3β, thereby promoting GLI2 stability and nuclear translocation, then modulating the role of HH pathway activity in GBM angiogenesis, metastasis, cell proliferation and cancer stem cell (CSC) regeneration. In addition to influencing mTORC1/2 and HH pathway interactions, GLI2 also affects HH and Wnt pathways and has an important role in GBM stem cell (GSC) maintenance. GLI2 knockdown using lentiviral-mediated shRNA downregulated HH-related and Wnt signaling pathway-related genes, including leucine-rich repeat-containing G-protein coupled receptor 5, inhibited tumor cell proliferation and invasive capacity, and induced apoptosis (81). Takezaki et al (7) indicated that overexpression of GLI2DC, a C-terminal truncated form of GLI2, antagonized GLI1 transcription factor function, inhibited glioma-initiating cell proliferation in culture and neoplasms occurring in organisms; glioma-initiating cell proliferation was prevented by clipping glial downstream factor cell division cycle 2 (CDC2). These results suggested that the HH/GLI1/CDC2 signaling cascade has an important role in glioma-initiating cell proliferation and malignancy. Since GLI2 affects downstream multiple carcinogenic and cancer-inhibiting pathways and is a key player in the network of neoplastic microenvironments, the possibility of blocking multiple pathways by targeting GLI2 may be a promising strategy.

Expression and role of PTC1 in GBM. PTC1 is the receptor of HH protein. In vertebrates, two PTC1 homologs have been isolated: PTC1 and PTC2 (82). PTC1 is mainly expressed in SHH protein-producing mesenchymal cells, while PTC2 is expressed in skin and testicular epithelial cells (83). A large clinical cohort study using the TCGA-GBM database detected GLI1 expression in relation to PTC1. The strong correlation between GLI1 and PTC1 expression was indicated to be a potential marker of HH-pathway activity (84), since PTC1 is a true target of GLI1 transcription factors (85) and its expression is expected to increase with the activity of GLI1 (5). Marjanovic Vicentic et al (86) reported increased expression of HH ligand-receptor PTC1 and HH effectors GLI1 and GLI2 in U87 and U251 cells overexpressing SOX3. BBF2H7 is an endoplasmic reticulum stranded transmembrane basic leucine zipper transcription factor that binds to HH ligand and PTC1 to promote the formation of ligand-receptor complexes, thereby activating HH signal transduction (87). Iwamoto et al (88) further indicated that the c-terminal end of secreted lumen BBF2H7 participates in HH ligand-dependent GBM proliferation by binding to HH ligands and PTC1 to activate HH signaling. Therefore, SOX3 and BBF2H7C terminals may become novel targets for anticancer drug development.

HH signaling pathway and the role of GSC in GBM. The HH, mTOR, Notch and Wnt/β-catenin signaling pathways are important signaling pathways that regulate GSC stemness and self-renewal (27,89,90). However, the self-renewal and abnormal differentiation of GSCs and their ability to promote the formation of drug resistance to RT and chemotherapy are the main reasons for the recurrence and invasion of GBM after conventional treatment (91,92). The mechanisms of how GSCs during invasion through the HH pathway, particularly in the face of complex and changing brain tissue anatomy, are presented in Fig. 2.

It has been reported that related homolog genes [e.g. Quaking homolog 1] (93), as well as transcription factors (e.g. Nanog homeobox) (94) and sialidase (e.g. neuroaminidase 4 (95)) are able to activate the HH signaling pathway to maintain the self-renewal ability of GSCs by increasing SHH/GLI1 expression. This may promote the development of stem-like traits of GSCs and the formation and migration of GBM cell spheres (93-95). In addition, scaffold protein discs large homolog 5 (DLG5) is a differentiation inhibitor 1 (ID1) regulate HH pathways by inhibiting downstream target ubiquitination (e.g. GLI1/2) and reducing GLI1/2 degradation (27,96). Cullin-3 interacts with GLI1/2 and dishevelled segment polarity protein 2 and induces degradation through ubiquitination (27). ID1 and DLG5 inhibit cullin-3 ubiquitin ligase, activate HH signaling and promote GSC proliferation and tumorigenicity (27,96). Park et al (97) demonstrated that dihydro pyrimidine-associated protein 5 (DRP5) is particularly upregulated in the proneural (PN) subtype of GSC and has a key role in maintaining GSC characteristics, including tumor globule formation, stem cell marker expression and xenograft tumor growth, and DRP5 is considered to be a functional biomarker of GBM derived from PN-GSCs. The emergence and maintenance of CSCs are usually controlled by the tumor microenvironment. The tumor microenvironment always provides metabolic challenges to cancer cells and CSCs, mainly due to tissue hypoxia. Mondal et al (98) revealed that nutritional deprivation-induced enhanced the expression of specific biomarkers for GSCs, with higher invasiveness and angiogenic characteristics. These cells induced by microenvironmental nutritional stress (NS) have a high xenoflux capacity and are therefore resistant to numerous anticancer drugs. The mechanism is that NS activates the Wnt and HH signaling pathways by regulating the β/β-catenin axis of β-catenin and GLI1, respectively. Vascular endothelial cells in the tumor microenvironment may provide SHH to further activate HH signaling pathways, thereby promoting GSC properties (99).

In summary, the neurobiology and basement membrane invasiveness of neural stem cells involves multiple molecular pathways that are interrelated. Therefore, targeting
5. Targeting the HH signaling pathway in GBM

The increased understanding of the key role of HH signaling in cancer has led to the development of pathway-specific inhibitors and the reuse of existing drugs that regulate HH/GLI (Table I). Drugs currently used in the clinic target SMO; among them, Vismodegib and Sonidegib have been approved by the US Food and Drug Administration for the treatment of basal cell carcinoma (BCC) (100,101) and medulloblastoma (101). However, mutations leading to drug resistance may occur, and thus, compounds that inhibit HH signaling downstream of SMO are urgently required and further research on the effects of HH/GLI pathway modulators in combination with anticancer drugs should be performed in order to provide evidence to pave the road for the future use of the combination of HH/GLI inhibitors and anticancer drugs.

Targeted therapy for GBM microenvironment. The mechanisms of GBM cell migration and invasion are complex and involve a series of mechanisms, including adhesion of GBM cells to the extracellular matrix (ECM) and ECM remodeling and degradation (102). As with other malignant tumor types, the growth, metastasis and invasion of GBM also depend on tumor angiogenesis. Although gliomas are characterized by hypervascularization, there are unavoidable disadvantages to anti-angiogenesis, such as reactive resistance mediated by the tumor microenvironment, and invasion and metastasis of tumor cells activated by hypoxia responses (103,104). During invasion and metastasis, GBM cells lose the polarized phenotype of epithelial cells and acquired mesenchymal characteristics, which is referred to as EMT (105). EMT is an active, drug-resistant, low-proliferative transient state that is frequently a feature of cancer as a whole but is seen in GBM in particular (106-108). Tubasatin A, a histone deacetylase 6 (HDAC6) inhibitor, reduced the expression of mesenchymal markers in GBM cells and contributed to the reversal of EMT (109). Feng et al (110) developed a pegylated poly (lactic acid) based nano-drug delivery system (nanoparticles) and modified CK peptides on its surface via GYG connectors to promote multitargeted delivery of Paclitaxel vasculogenic mimicry channels, tumor neovascularization and glioma cells. Similarly, Kast et al (111) proposed the EIS regimen (combination of itraconazole, metformin, naproxen, pirfenidone, quetiapine and rifampicin) that was able to safely and effectively block EMT of GBM. GBM progression may be inhibited by targeting tumor angiogenesis and EMT. Although these animal models are not perfect, they may be used to explore the effectiveness of new treatments for GBM prior to clinical phase I/II studies.

The HH signaling pathway is closely related to PC function, and thus, inhibiting PC function may help inhibit GBM proliferation, malignant development and treatment...
resistance (112). A previous study reported that the development of resistance to acquired kinase inhibitors is associated with upregulation of PC, uncontrolled PC length and abnormal activation of SHH signaling. Knockdown of KIF7 was observed to control the length and integrity of the PC and re-sensitize GBM cells (113). In addition, Dynarrestin was able to reversely inhibit intraflagellar transport of SMO flux in PC and inhibit HH pathway-dependent neuronal precursors and tumor cell proliferation (23). Therefore, Dynarrestin is a promising compound for the pharmaceutical development of anticancer drugs.

**Inhibition of the HH/GLI pathway.** HH signaling has been reported to be abnormally activated in >30% of solid tumor types, including GBM (62,114). Abnormal activation of the SHH pathway is associated with GBM resistance to temozolomide (TMZ) and the reason is the high expression of methylguanine methyltransferase (MGMT), which reverses the effects of TMZ on DNA (115,116) and confers cell protection from TMZ-induced death by silencing three genes: MutS homolog 2 (a DNA repair protein involved in MMR), PTCH2 and chloride channel accessory 2 (a type 1 transmembrane protein that inhibits the Wnt pathway) (24). Resistance to TMZ was only slightly reversed by MGMT inhibitor O6-benzylamine, but a marked further enhancement was achieved by addition of Honokiol (117). Furthermore, the invasion of GBM was reported to be associated with the presence of CSCs and the SHH pathway has an important role in the maintenance and proliferation of CSCs (118,119). After inhibiting SHH, LDE225 slowed down the growth of GBM and downregulated PTCH1 and GLI1 in vivo (120). CSCs preferentially activate the DNA damage checkpoint response and exhibit enhanced DNA repair ability; thus, SHH signaling via GLI1 in CSC has a role in GBM resistance to TMZ (121).

Glabrescione B is the first small molecule to bind to GLI1 zinc fingers, impelling GLI1 activity by interfering with its interaction with DNA. Thus, it inhibits the ability of HH-dependent tumor stem cells to self-renew and clado-genesis. The determination of the structural requirements for GLI1/DNA interactions highlights their relevance to drug interference with GLI signaling (10). Melamed et al (122) developed polyethylene imine-coated spherical nucleic acid nanoparticles (PEI-SNAs) targeting GLI1. GLI1 PEI-SNAs bind scavenger receptors on GBM cells and undergo endocytosis in a pit/lipid raft/dynein-dependent manner, promoting the silencing of HH pathway genes and downstream target genes. These genes promote an aggressive, drug-resistant GBM phenotype. GLI1 PEI-SNAs not only significantly increased the sensitivity of nerve spheres to chemotherapy, but also further impaired the formation of dry nerve spheres (123).

### Table I. List of hedgehog pathway inhibitors used in GBM.

| Inhibitor name | Drug combination | Target | Mode of action | Reverse resistance | (Refs.) |
|---------------|------------------|-------|----------------|--------------------|--------|
| Dynarrestin   | (-)              | PC    | Inhibition of the flow of SMO in PC | (-) | (112) |
| O6-benzylamine| Honokiol(+)      | SHH   | Antagonist of MGMT | (+) | (117) |
| LDE225        | (-)              | SHH   | Downregulated PTCH1 and GLI1 | (-) | (120) |
| PEI-SNAs      | (-)              | GLI1  | Binding to clearance receptors on GBM cells | (+) | (123) |
| GANT-61       | TMZ              | SHH   | Increases production of ROS | (+) | (124) |
| GANT-61       | (-)              | SHH   | Increases the expression of LC3 II and cleaved caspase 3 and 9 | (-) | (125) |
| Curcumin      | MicroRNA-326     | SHH/GLI1 | Antagonist of SHH/GLI1 | (-) | (126) |
| XH30          | (-)              | GLI1  | Decreases GLI1 activity | (+) | (127) |
| Phosphorylated peptides | (-) | GLI2  | Decreases GLI2 activity | (-) | (128) |
| Tubasatin A   | (-)              | SHH/GLI1 | Downregulation of GLI1 and PTCH1/2 receptors | (-) | (129,130) |
| CGT-2         | (-)              | GLI1  | Antagonist of SMO | (+) | (132) |
| Capsulated propylamine | (-) | GLI1  | Inhibition of GLI1 expression | (+) | (136) |
| PF403         | (-)              | SMO/GLI1 | Antagonist of SMO/GLI1 | (+) | (137) |

PC, primary cilia; TMZ, temozolomide; SMO, smoothened; MGMT, methylguanine methyltransferase; PEI-SNAs, polyethylene imine-coated spherical nucleic acid nanoparticles; ROS, reactive oxygen species; CGT-2, cyclodopamine glucuronoside precursors; PF403, 13A(S)-3-hydroxy-6,7-dimethoxyphenanthro[9,10-b]-indolizidine; GLI, glioma-associated oncogene; GBM, glioblastoma; SHH, Sonic Hedgehog; PTCH, patched; LC, light chain.
Arsenic trioxide also significantly reduced the clado genesis of tumor neuroglobules by inhibiting the HH pathway, inhibiting the proliferation of GBM neuroglobules and promoting apoptosis (124). The combination of the SHH inhibitor GANT-61 with TMZ increased the cytotoxic effect of TMZ and the combination of GANT-61 with TMZ increased the production of reactive oxygen species in GBM cells, suggesting that inhibition of the SHH pathway may sensitize GBM cells to the effects of TMZ by increasing oxidative stress (114,124). GANT-61 induced apoptosis and autophagy in GBM cells by increasing the expression of light chain 3II and lysed Caspase-3 and -9 (125). Furthermore, GLI inhibition combined with TMZ increased the apoptosis rate of glioma stem cells by 6.8-fold, thereby reducing the size and number of nerve spheres grown from glioma stem cells (115). Yin et al (126) reported that the combination of tumor suppressor gene miR-326 and curcumin significantly inhibited the SHH/GLI1 pathway of glioma cells, independent of the P53 status, significantly increased apoptosis and reduced the proliferation and migration of glioma cells. Similarly, Ji et al (127) reported that a novel PI3K inhibitor, XH30, inhibited tumor growth that was resistant to TMZ. In terms of the mechanism, the role of XH30 may be to reverse the activation of GLI1 induced by SHH by atypical HH signaling and to reduce GLI1 activation by insulin-like growth factor 1 (127). Thus, XH30 may be a novel treatment option for TMZ-resistant GBM.

Traditional treatments for GBM include systemic chemotherapy, RT and surgery. Han et al (128) synthesized three phosphorylated peptides derived from GLI2 and combined them with the cell-penetrating peptide TAT-[47-57] AYGRKKRRQRRR. The three mixed phosphorylated poly-peptides derived from GLI2 significantly increased the level of GLI2 phosphorylation and decreased the transcriptional activation of GLI2, and the radiation sensitization of GBM cells was significantly higher than that in the control group (128). HDAC6 was upregulated in GSCs and inhibited HDAC6 down-regulated glioma-associated oncogene GLI1 and PTC1/2 receptors, as well as SHH signaling components, expression and activity, thereby inhibiting GSC proliferation, inducing differentiation and increasing the apoptosis rate through the SHH/GLI1 signaling pathway (109,129). Inhibition of HDAC6 by Tubasatin A enhanced the radiosensitivity of GBM tumor cells. The mechanism may be that HDAC6 inhibits checkpoint kinase (CHK)1 degradation induced by down-regulation of X-linked inhibitor of apoptosis, which reduced the DNA damage repair ability of GSCs, leading to increased radiosensitivity (109,130).

In summary, target genes associated with the SHH/GLI pathway provide promising new drug targets for inhibiting GBM proliferation, as well as overcoming drug resistance and radiation resistance of GSCs.

**SMO inhibitors.** The steroidal alkaloid cyclopamine, an antagonist of the HH coreceptor SMO, acts as an inhibitor of the HH pathway (131). To limit the toxicity of cyclopamine to HH-dependent non-tumor cells, cyclopamine precursor drugs [e.g., cyclopamine glucuronoside precursor drugs (CGP-2) and 1b] are commonly used (132,133). It was indicated that CGP-2 inhibits the HH pathway more effectively than conventional TMZ adjuvants (131). In the presence of β-glucuronidase, the activated prodrug 1b was toxic and downregulated the HH target gene GLI1 in C6 cells and C6-CSCs (132). In U251 cells, tyramine not only inhibited the HH/GLI1 signal transduction pathway, leading to decreased MGMT expression, but also induced cell apoptosis by activating caspase-3 cleavage, thus leading to increased sensitivity of GBM to TMZ (133). However, the combination of aceterminazine and TMZ enhanced the dryness and drug resistance of GBM cells by inducing the expression of SOX-2 and OCT-4 and may lead to tumor recurrence in patients (134). Therefore, the best therapeutic strategy is to first inhibit the SHH pathway and then administer TMZ (134,135). Liu et al (136) found that the combination of capsulated propylamine and TMZ had synergistic cytotoxic effects and was more likely to inhibit the ability to induce apoptosis and eliminate neuroglobin formation by inhibiting GLI1 expression. Therefore, MCyp may be used as a tumor stem cell inhibitor to prevent tumor recurrence. Future efforts should be made to investigate the possibility of using HH pathway inhibitors prior to conventional chemotherapy in patients with GBM. Future efforts should focus on the efficacy of HH pathway inhibitors prior to systemic chemotherapy in patients with GBM.

Chen et al (137) indicated that PF403 inhibits cell surface Smoothened (Smo) receptor aggregation at the molecular level by directly binding or enhancing the interaction between Smo and the suppressor PTC1H1. In addition, PF403 significantly inhibited the transcription of GLI1 and its accumulation in the nucleus by promoting the interaction between SUFU-GLI1 and PKA-GLI1, blocking the HH signaling pathway of T98G MGMT-expressing cells, and downregulated the expression of MGMT. Inhibition of the HH pathway by PF403 counteracted TMZ resistance and the precursor Cat3 of PF403 enhanced the anti-tumor activity of TMZ in vivo (137,138). In summary, Cat3 is a promising therapeutic agent for HH-driven GBM.

6. **HH pathway and immunotherapy**

The key to antitumor immunity is that antigen-presenting cells (APCs) engulf tumor cells. TMZ may induce an endoplasmic reticulum stress response, and the combination of CD47 blocker and TMZ may produce significant phagocytosis (139,140). Increased tumor cell phagocytosis, enhanced antigenic cross-presentation in APC and activation of cyclic GMP-AMP interferon gene synthase stimulation leads to more efficient T-cell effects. This connection between innate and adaptive responses inhibits GBM growth while also activating immune checkpoints. Sequential administration of an anti-programmed cell death protein 1 (anti-PD1) antibody overcomes this potential adaptive resistance (140). However, the mechanism by which anti-PD1 antibodies reverse GBM resistance through HH signaling remains to be elucidated. It has been reported that GANT-61 is able to reduce the expression of PD-L1 and the proliferation of tumor cells in vivo and in vitro by using organic compound drugs for human gastric cancer. Of note, anti-PD-L1 antibodies induced apoptosis of tumor cells in organs of GLI2-expressing mice. Studies suggested that GLI2 expressed in gastric cancer cells is an internal regulator of PD-L1 and promotes tumor growth by inhibiting the anti-tumor response (141,142). In summary, the HH pathway may become a new immunotherapy target for GBM after further study.
7. Discussion

The biological treatment of GBM has been studied for numerous years, but the treatment of deadly cancers still poses a great challenge. GBMs are highly invasive and susceptible to drug resistance, resulting in a high mortality rate, and GBM accounts for 2.9% of cancer-related deaths (143).

A key treatment issue for GBM is the high degree of heterogeneity within the tumor. This heterogeneity further complicates the differences among patients with GBM. In addition to heterogeneity, GBM also has GSCs that contribute to tumor proliferation, maintenance and drug resistance (144,145), and GSCs may respond differently to TMZ or ionizing radiation (146). All of this makes routine treatment difficult. Further research is required on the impact of GBM heterogeneity on modern therapies, including molecular immunotherapy and personalized therapy. The lymphocytes present in GBM have an increased proportion of CD4+T cells and FOXP3+ regulatory T cells may induce signaling pathways that inhibit immune responses (147,148), e.g., the expression of IDO enzyme and STAT3 signals (149,150). However, GBM tumor-infiltrating effector lymphocytes were observed to be rare (151,152). This may also be the reason why a clinical trial of immune checkpoint blocking using the anti-PD1 antibody nivolumab (NCT02017717) used in patients with newly diagnosed or relapsed unmethylated GBM (153), have not been successful. The currently used immunotherapy for GBM may be broadly divided into vaccine therapy, immune checkpoint blocking, oncolytic virus therapy and chimeric antigen receptor T-cell therapy (154-156). In addition to immunotherapy, EGFR using tyrosine kinase inhibitors (TKI), VEGF TKI and targeted therapies for the PI3K/mTOR pathway have also been explored in GBM. However, a phase 3 trial of deatuxizumab mandolin in combination with standard therapy for the treatment of newly diagnosed EGFR-amplified GBM was terminated early for being ineffective (157), and mTOR inhibitors such as everolimus (NCCTG057K) and Taxotaxim (EORTC26082) also proved to lack efficacy in phase 2 trials (158,159). A phase 2 trial of regorafenib (REGOMA) in a relapsed setting indicated a therapeutic OS benefit compared to lomustine, but the drug had minimal activity; thus, VEGF monotherapy may have a limited effect in a non-selected population (160).

It is necessary to study new targets for the treatment of GBM. HH signaling has emerged as an attractive target for cancer therapy and several HH inhibitors have been designed. To date, SMO inhibitors were proven to have satisfactory efficacy in BCC and medulloblastoma (100,101), but clinical trials for other cancer types, such as colorectal, pancreatic or lung cancers, have yielded poor results (161-163). In preclinical studies, compared with HH and SMO inhibitors, GLI inhibitors had better anticancer efficacy (164,165). In addition, GLI inhibitors effectively inhibited the growth of numerous GLI-dependent cancers by targeting the GLI-regulated SMO-independent pathway (166). As for inhibitors of GLI1 and GLI2 transcription factors, the anticancer drug arsenic trioxide is currently the only drug undergoing clinical trials in solid tumors and hematological malignancies (167). Although the use of HH inhibitors in GBM has not been extensively investigated, numerous studies suggested that HH inhibitors in combination with conventional therapies may markedly increase efficacy and reduce the incidence of drug resistance (124-126,133,137). Of course, this also requires a large number of clinical trials to further verify whether HH inhibitors are beneficial to the therapeutic efficacy of GBM.

Epigenetic regulators interact with drivers of GBM stem cell-like cell proliferation. These drivers include Notch, HH and WNT pathways. Previous studies suggested that these signaling pathways may perform cross-talk with SHH signaling pathways (27,71,80-81,89,90), which means that these signaling pathways may be activated simultaneously in different tumor types. WNT/β-catenin interacts with the SHH pathway through GLI1 and GLI2 by regulating the expression of secreted crimp-related proteins. SHH signaling was inhibited by GSK3β, a component of the WNT signaling pathway. In certain tumor types, upregulation of the WNT signaling pathway occurs sequentially when the SHH pathway is inhibited (168). In addition, the synergistic effect of the inhibition of the SHH and PI3K/AKT/mTOR signaling pathways may inhibit the proliferation of glioblastoma-initiating cells (GICs), tumor growth and the formation of neural spheres and clones, and induce cell apoptosis (169). Combined drug action targeting two pathways or inhibition at the intersection of two pathways may be a good breakthrough point for targeted therapy.

8. Conclusion

Current conventional therapies for GBM are ineffective due to drug resistance issues and resistance may be overcome through a combination of HH inhibitors or multilevel HH signaling cascades, such as combinations of multiple targeted HH drugs and multi-target HH inhibitors. In addition to pioneering new approaches based on existing scientific theories, the effectiveness of evaluating these therapies in clinical trials requires to be further improved. This includes increasing the number of patients with GBM in phase I trials of HH pathway inhibitors, thereby providing more complete clinical trial data for the development of more effective targeted therapeutic strategies.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

HW performed the literature search and selection. XX was responsible for the conception, analysis and design of the study. HW and XX were major contributors in writing of the manuscript. DW and JP participated in the coordination of the study and reviewed the manuscript. BT and YG were responsible for the revision of the manuscript. QL and ZG were responsible.
for the literature search and design of the study. All authors read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Garney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, et al: American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18 (Suppl 1): i1-150, 2016.
2. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 20 (Supp 14): i1-vi86, 2018.
3. Vadaoonkar K, Epari S, Chinhasawamy V, Krishnathy R, Tonse R, Gupta T and Jalali R: Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population. Childs Nerv Syst 34: 1489-1495, 2018.
4. Hussein O, Zebratt G, Block R, Boscia A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 20 (Supp 14): i1-vi86, 2018.
5. Chandra V, Das T, Gulati P, Biswas NK, Rote S, Chatterjee U, Ghosh N, Deb S, Saha SK, Chowdhury AK, et al: Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete/low clusters. PLoS One 10: e0116390, 2015.
6. Azzi S, Treps L, Leclair HM, Ngo HM, Harford-Wright E, Takezaki T, Hide T, Takanaga H, Nakamura H, Kuratsu J and Chang J, Guo C, Li J, Liang Z, Wang Y, Yu A, Liu R, Guo Y, Cammarata FP, et al: The hallmarks of glioblastoma: Heterogeneity, intercellular crosstalk and molecular signature of invasiveness and progression. Biomolecules 10: 806, 2022.
7. Charuhas B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, et al: Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol 18: 549-556, 2016.
8. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heideck V, Kirson ED, Tailibert S, Liebermann F, Dhaly V, et al: NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 48: 2192-2202, 2012.
9. Höing S, Yeh TY, Baumann M, Martinez NE, Habenberger P, Kremer L, Drexler HCA, Küchler P, Reinhardt P, Choidas A, et al: Dynarrestin, a novel inhibitor of cytoplasmic dynein. Cell Chem Biol 24: 357-369.e6, 2018.
10. Rocha CRR, Reilly Rocha A, Molina Silva M, Rodrigues Gomes L, Teatin Latancia M, Andrade Tomaz M, de Souza A, Fortunato A, et al: Hedgehog signaling pathway: Carcinogenesis and targeted therapy. Iran J Cancer Prev 6: 36-43, 2013.
11. Jin X, Jeon HM, Jin X, Kim EJ, Yoon Y, Oh SY, Kim JK, Kim SH, et al: The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in glioblastoma stem cells. Cell Rep 16: 1629-1641, 2015.
12. Louis DN, Perry A, Reifenberger G, von Deimling A, Berlin K, Reifenberger J, Preusser M, Jouvet A, et al: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 131: 803-820, 2016.
13. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Sin I, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
14. Ceccarelli M, Barthel FP, Malta TM, Sabelot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagonita SM, et al: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164: 550-563, 2016.
15. Wang Q, Hu B, Hu X, Kim H, Squarrito M, Scarpalese L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32: 12-42, 2017.
16. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et al: Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat Rev Cancer 14: 92-107, 2014.
17. Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, et al: Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol 18: 549-556, 2016.
18. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heideck V, Kirson ED, Tailibert S, Liebermann F, Dhaly V, et al: NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 48: 2192-2202, 2012.
19. Hsueh O, Zebratt G, Block R, Boscia A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol 21 (Suppl 5):v1-v100, 2019.
20. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, et al: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 22: 1583-1588, 2004.
21. Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, et al: Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol 18: 549-556, 2016.
22. Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heideck V, Kirson ED, Tailibert S, Liebermann F, Dhaly V, et al: NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. Eur J Cancer 48: 2192-2202, 2012.
23. Höing S, Yeh TY, Baumann M, Martinez NE, Habenberger P, Kremer L, Drexler HCA, Küchler P, Reinhardt P, Choidas A, et al: Dynarrestin, a novel inhibitor of cytoplasmic dynein. Cell Chem Biol 24: 357-369.e6, 2018.
24. Rocha CRR, Reily Rocha A, Molina Silva M, Rodrigues Gomes L, Teatin Latancia M, Andrade Tomaz M, de Souza A, Fortunato A, et al: Hedgehog signaling pathway: Carcinogenesis and targeted therapy. Iran J Cancer Prev 6: 36-43, 2013.
25. Jin X, Jeon HM, Jin X, Kim EJ, Yoon Y, Oh SY, Kim JK, Kim SH, et al: The ID1-CULLIN3 axis regulates intracellular SHH and WNT signaling in glioblastoma stem cells. Cell Rep 16: 1629-1641, 2015.
26. Huyh DL, Koh H, Chandimali N, Zhang JJ, Kim N, Kang TY, Ghosh M, Gera M, Park YH, Kwon T and Jeong DK: BRM270 inhibits the proliferation of CD44 positive pancreatic ductal adenocarcinoma cells via downregulation of sonic Hedgehog signaling. Evid Based Complement Alternat Med 2019: 8620469, 2019.
27. Marigo V and Tabin CJ: Regulation of patched by sonic Hedgehog in the developing neural tube. Proc Natl Acad Sci USA 93: 9346-9351, 1996.
28. Plotnikova OV, Golemis EA and Pugacheva EN: Cell cycle-dependent ciliogenesis and cancer. Cancer Res 68: 2058‑2061, 2008.
29. Mastronardi FG, Dimitroulakos J, Kamel‑Reid S and Plotnikova OV: Cell cycle-dependent ciliogenesis and cancer. Cancer Res 68: 2058‑2061, 2008.
30. Plotnikova OV, Golemis EA and Pugacheva EN: Cell cycle-dependent ciliogenesis and cancer. Cancer Res 68: 2058‑2061, 2008.
31. Plotnikova OV, Golemis EA and Pugacheva EN: Cell cycle-dependent ciliogenesis and cancer. Cancer Res 68: 2058‑2061, 2008.
32. Alexandre C, Jacinto A and Ingham PW: Transcriptional activation of Hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins. Genes Dev 10: 2003-2013, 1996.
Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Noman AS, Uddin M, Rahman MZ, Nayeem MJ, Alam SS, Wang K, Pan L, Che X, Cui D and Li C: Sonic Hedgehog/GLI1 signaling pathway inhibition restricts cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma. Mol Med Rep 12: 9064‑9068, 1992.

Martinez-Outschoorn U, Sotgia F and Lisanti MP: Tumor microenvironment and metabolic synergy in breast cancers: Critical importance of mitochondrial fuels and function. Semin Oncol 41: 195‑216, 2014.

Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F and Lisanti MP: Understanding the metabolic basis of drug resistance: Therapeutic intervention of the Warburg effect kills cancer cells. Cell Cycle 10: 2521‑2528, 2011.

Wang Y, Zhao D, Liu HP, Wang YS, Kang P, CL, Du WZ, Wang HJ, Liu X, Zhang ZR and Jiang CL: Activation of sonic Hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway. J Exp Med 161: 674‑678, 2014.

Rowitch DH, S‑Jacques B, Lee SM, Flax JD, Snyder EY and McMahon AP: Sonic Hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci 19: 1798‑1803, 1999.

Riobo‑Del Galdo NA, Lara Montero Á and Wertheimer EV: A comprehensive review. Bosn J Med Sci 18: 8‑20, 2019.

Singh AC, Shivaiah P, Karthick V, Kardam V, Vranic S and Serman L: Sonic Hedgehog pathway pathway inhibition restricts cell migration and invasion by induction of matrix metalloproteinase. Oncotarget 6: 13899‑13913, 2015.

Tschaikner P, Enzler F, Torres‑Quesada O, Aanstad P and Méthot N and Basler K: Sonic Hedgehog enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma. Mol Med Rep 12: 6702‑6710, 2015.

Kloepper J, Riedemann L, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Hartik J Jr, Fischer W, Lukas J, et al: Autocrine VEGF/VEGFR2‑neuropilin‑1 signaling promotes glioma stem‑like cell viability and tumor growth. J Exp Med 209: 507‑520, 2012.

Kloepfer J, Riedemann L, Amoozgar Z, Seano G, Susek K, Xu X, Dalvile N, Anjorin M, Diatta M, Song JW, et al: Ang‑2/VEGF bicspecific antibody reprograms macrophages and resident microglia to anti‑tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 113: 4476‑4481, 2016.

Chen, L, Wang L, Qin J and Wei DS: CtBP2 interacts with ZBTB18 to promote malignancy of glioblastoma. Life Sci 262: 118477, 2020.

Bensalma S, Turpault S, Balandre AC, De Boissiviers M, Gaillard A, Chadaene C and Muller JM: PKA at a cross‑road of Hedgehog signaling pathway pathway inhibition restricts cell migration and invasion in human gliomas. Neurol Res 37: 975‑980, 2015.

O'Connell S, Jeffs AR and Tyndall JD: Variable expression of Hedgehog signaling pathway inhibition restricts cell migration and invasion. Cancer Res 69: 6790‑6798, 2009.

Kamermuker J, Devos V, Vermeulen MJ, Michiels L, Rousset F, Keryer V, Schmitz J, Schmitt G, Friess HW, Petryk A, et al: The role of Hedgehog signaling pathway inhibition restricts cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway. J Exp Med 161: 674‑678, 2014.
Chantaravisoot N, Wongkongkathep P, Loo AJ, Mischel SP and Maiti S, Mondal S, Satyavarapu EM and Mandal C: mTORC2

Sargazi ML, Juybari KB, Tarzi ME, Amirkhosravi A, Zhang Z, Zheng X, Luan Y, Liu Y, Li X, Liu C, Chen X and Zhu H, Carpenter RL, Han W and Lo HW: The GLI1 splice

de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y and Han B, Wang R, Chen Y, Meng X, Wu P, Li Z, Duan C, Li Q, Li Y, Huang S: Gli1‑induced deubiquitinase USP48 aids glioblastoma development and Hedgehog signaling in tumor stem cells. Neuro Oncol: noac001, 2022 (Epub ahead of print).

Park MG, Seo S, Ham SW, Choi SH and Kim H: Dihydropyrimidinase‑related protein 5 controls glioblastoma stem cell characteristics as a biomarker of proneural‑subtype glioblastoma stem cells. Oncol Lett 20: 1153‑1162, 2020.

Mondal S, Bhattacharya K and Mandal C: Nutritional stress reprograms dedifferentiation in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: A stochastic model of cancer stem cells. Cell Death Discov 4: 110, 2018.

Yan GN, Yang L, Ly VF, Shi Y, Shen LL, Yao XH, Guo QN, Zhang C, Cui YH, Zhang X, et al: Endothelial cells promote stem‑like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 234: 11‑22, 2014.

Zaphiropoulos PG, Undén AB, Rahnama F, Hollingsworth RE: Activation of C6 glioblastoma cell line: A possible role of Hedgehog signaling pathway. Mol Biol Rep 48: 6413‑6421, 2021.

Zhang P, Cui YH, Zhang X, et al: Endothelial cells promote stem‑like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 234: 11‑22, 2014.

Park MG, Seo S, Ham SW, Choi SH and Kim H: Dihydropyrimidinase‑related protein 5 controls glioblastoma stem cell characteristics as a biomarker of proneural‑subtype glioblastoma stem cells. Oncol Lett 20: 1153‑1162, 2020.

Mondal S, Bhattacharya K and Mandal C: Nutritional stress reprograms dedifferentiation in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: A stochastic model of cancer stem cells. Cell Death Discov 4: 110, 2018.

Yan GN, Yang L, Ly VF, Shi Y, Shen LL, Yao XH, Guo QN, Zhang C, Cui YH, Zhang X, et al: Endothelial cells promote stem‑like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 234: 11‑22, 2014.

Zaphiropoulos PG, Undén AB, Rahnama F, Hollingsworth RE: Activation of C6 glioblastoma cell line: A possible role of Hedgehog signaling pathway. Mol Biol Rep 48: 6413‑6421, 2021.

Zhang P, Cui YH, Zhang X, et al: Endothelial cells promote stem‑like phenotype of glioma cells through activating the Hedgehog pathway. J Pathol 234: 11‑22, 2014.
114. Carpenter RL and Lo HW: Hedgehog pathway and GLI1 isoforms in human cancer. Discov Med 13: 105-113, 2012.

115. Honorato JR, Hauser-Davis RA, Saggioro EM, Correia FV, Sales-Junior SF, Soares LOS, Lima LDR, Moura-Neto V, Lopes GPF and Spohr TCLS: Role of sonic Hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma. J Cell Physiol 235: 3798-3814, 2020.

116. Melamed JR, Morgan JT, Ioele SA, Gleghorn JP, Sims-Mourtada J and Day ES: Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide. Oncotarget 9: 27000-27015, 2018.

117. Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, Chuang SE, Hu TS, Lai TY and Lai GM: Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by an anti-EGF in glioblastoma multiforme cells. PLoS One 10: e1014830, 2015.

118. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 7900-2908, 2008.

119. Munoz JL, Rodriguez-Cruz V, Walker ND, Greco SJ and Rameshwar P: Temozolomide resistance and tumor recurrence: Halting the Hedgehog. Cancer Cell Microenviron 2: e747, 2015.

120. Hung HC, Liu CC, Chuang YJ, Su CL and Gean PW: Inhibition of sonic Hedgehog signaling suppresses glioma stem-like cells likely through inducing autophagic cell death. Front Oncol 10: 1233, 2020.

121. Chen J, Fu X, Wan Y, Wang Z, Jiang D and Shi L: miR-125b inhibitor enhances the chemosensitivity of glioblastoma stem cells to temozolomide by targeting BAK1. Tumour Biol 35: 6293-6302, 2014.

122. Melamed JR, Ioele SA, Hannum AJ, Ullman VM and Sims-Mourtada J: Polyethyleneimine-spherical nucleic acid nanoparticles against GLI1 reduce the chemoresistance and stemness of glioblastoma cells. Mol Pharm 15: 5135-5145, 2018.

123. Ding D, Liu X, Wang H, Han B, Cui Y, Yang D, Chen H, Liu D, Liu X, Zhai X and Jiang C: MicroRNA-326 sensitizes human glioblastoma cells to temozolomide via the SHH/GLI1 signaling pathway. Acta Neuropathol Commun 2: 31, 2014.

124. Wang J, Huang S, Tian R, Chen J, Gao H, Xie C, Shan Y, Zhang Z, Gu S and Xu M: The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK. Oncotarget 9: 14413-14427, 2018.

125. Carballo GB, Ribeiro JH, Lopes GPF, Ferrer VP, Dezonne RS, Melamed JR, Ioele SA, Hannum AJ, Ullman VM and Day ES: Replication study: The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Elife 6: e18173, 2017.

126. Melamed JR, Morgan JT, Ioele SA, Gleghorn JP, Sims-Mourtada J and Day ES: Replication study: The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Elife 6: e18173, 2017.

127. Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, et al: Tumour infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 110: 1518-1523, 2013.

128. Braun S, Oppermann H, Mueller A, Renner C, Hochmair S, Baran-Schnitzel R, Gebhardt R, Hippius A, Thiry J, Meixensberger J and Gauntt F: Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget 9: 37439-37457, 2018.

129. Gründ-Gröschke S, Stockmaier G and Aberger F: Hedgehog/GLI signaling in tumor immunity-new therapeutic opportunities and clinical implications. Cell Comm Signal 17: 172, 2019.

130. Surveillance, Epidemiology, and End Results Program: Cancer stat facts: Brain and other nervous system cancer, 2019. https://seer.cancer.gov/statfacts/html/brain.html. Accessed July 12, 2019.

131. Honing RJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, et al: Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 540: 227-232, 2017.

132. Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, Jiang T and Wu A: Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer 110: 2560-2568, 2014.

133. Heimberger AB, Abou-Ghazal M, Reina-Oritz C, Yang DS, Sun W, Qiao W, Hiraoka N and Fuller GN: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14: 5166-5172, 2008.

134. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao Z, Zhang L, et al: Durable therapeutic efficacy utilizing combinational blockade againstIDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20: 5290-5301, 2014.

135. Heimberger AB, Sun W, Hussian SF, Dey M, Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R, Schmitting B, et al: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro Oncol 10: 98-103, 2008.
151. Jackson CM, Choi J and Lim M: Mechanisms of immunotherapy resistance: Lessons from glioblastoma. Nat Immunol 20: 1100–1109, 2019.

152. Sampson JH, Fecci PE and Ashley DM: Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20: 12–25, 2020.

153. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al: Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol 6: 1003–1010, 2020.

154. Chiocca EA, Nassiri F, Wang J, Peruzzi P and Zadeh G: Viral and other therapies for recurrent glioblastoma: Is a 24-month durable response unusual? Neuro Oncol 21: 14–25, 2019.

155. Iorgulescu JB, Reardon DA, Chiocca EA and Wu CJ: Immunotherapy for glioblastoma: Going viral. Nat Med 24: 1094–1096, 2018.

156. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al: Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375: 2561–2569, 2016.

157. Lassman A, Pugh S, Wang T, Aldape K, Gan H, Preusser M, Vogelbaum M, Sultman E, Won M, Zhang P, et al: ACTR-21. A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in epidermal growth factor receptor (EGFR) amplified (AMP) newly diagnosed glioblastoma (nGBM). Neuro Oncol 21 (Suppl 6): vi17, 2019.

158. Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, et al: A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 17: 1261–1269, 2015.

159. H. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.